Search Hotels in Sausalito

The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks.

Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch

December 06, 2023

Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly

Decoding AbbVie's Options Activity: What's the Big Picture?

December 05, 2023

Via Benzinga

3 Stocks at the Forefront of Personalized Medicine Trend

December 05, 2023

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

December 04, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Analyst Ratings for AbbVie

December 01, 2023

Via Benzinga

ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note

December 04, 2023

AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $

Via Benzinga

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

December 04, 2023

No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.

AbbVie's $10.1 billion acquisition of ImmunoGen, with its promising ovarian cancer drug, Elahere, signals a strategic move in the competitive cancer drug market. Investors anticipate market reactions,...

Topics Bonds

Exposures Debt Markets

AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains

December 04, 2023

Via Talk Markets

Health Care Company AbbVie Announces Acquisition of Immunogen

November 30, 2023

Via Benzinga

AbbVie Should Consider a Dividend Cut -- Here's Why

November 30, 2023

Dividend Kings with above-average yields have been badly underperforming the broader markets.

The medical device maker's shares have gained a little more than 1% so far this year.

Medtronic Stock: Bull vs. Bear

November 29, 2023

These stocks offer much more than reliable dividends.

2 Dividend Stocks to Buy and Hold Forever

December 02, 2023

Investors are pocketing dividend yields between 4% and 9% with these stocks.

5 S&P 500 Stocks That Pay a Generous Dividend

December 02, 2023

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review

Topics Stocks

Exposures US Equities

December 01, 2023

Software earnings were strong, while the Fed is shifting toward rate cuts.

Via Investor's Business Daily

Topics Economy Stocks

Exposures Interest Rates US Equities

These biotechs targeting multiple neurodegenerative diseases

December 01, 2023

A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.

Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion.

How Is The Market Feeling About AbbVie?

November 24, 2023

Via Benzinga

ImmunoGen Stock Nearly Doubled On Thursday: What Happened?

November 30, 2023

Via Talk Markets

Why Abbvie Stock Popped Today

November 30, 2023

The company announces a major deal worth over $10 billion.

AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)...

ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal

November 30, 2023

Via Benzinga

Why Is ImmunoGen (IMGN) Stock Up 81% Today?

November 30, 2023

ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal.

IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere.

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

November 30, 2023

Via Investor's Business Daily

Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy

November 29, 2023

These are the best blue-chip stocks for investors to consider among a group of already strong equities available in the market.

AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal...

AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients

November 29, 2023

Via Benzinga

These are the top sectors for blue chip growth in 2024

November 29, 2023

The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.

J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown

Topics Economy Intellectual Property

Exposures COVID-19 Intellectual Property Interest Rates

J&J, Gilead, BMS: A look at undervalued dividend payers

November 29, 2023

We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.

Biotech And Healthcare Portfolio Playbook For December 2023/24

November 27, 2023

Via Talk Markets

3 Rising Stars: Invest Now in Tomorrow’s Trillion-Dollar Companies

November 26, 2023

If you are an investor looking for secret rising stars, explore these three that can reach trillion dollar status.

There's no time like the present to buy these stocks.

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later

November 26, 2023

Buying the stock at a cheap price today could help you achieve some great long-term returns.

Could AbbVie Stock Help You Become a Millionaire?

November 24, 2023